<html>
  <head>
    <title></title>
    <!-- Licensed to: SUMMIT
         Document created using EDGARfilings PROfile 7.0.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: center; font-weight: bold;">As filed with the Securities and Exchange Commission on June 10, 2020</div>
  <div style="text-align: center;">&#160;</div>
  <div style="text-align: right; font-weight: bold;">Registration No. 333-</div>
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center;"><font style="font-size: 12pt;">Washington, D.C. 20549</font><br>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM S-8</div>
    <div style="text-align: center; font-weight: bold;">REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: center;"><br>
    </div>
    <div style="text-align: center; font-size: 24pt; font-weight: bold;">BIOCRYST PHARMACEUTICALS, INC.</div>
    <div style="text-align: center; font-style: italic;">(Exact Name of Registrant as Specified in its Charter)</div>
    <div style="text-align: center; font-style: italic;"> <br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <br>
    <table cellspacing="0" cellpadding="0" border="0" id="z6313437b778a4cc69db4e1a931bbdaed" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Delaware</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">62-1413174</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-style: italic;">(State of Incorporation)</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-style: italic;">(I.R.S. Employer Identification No.)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">4505 Emperor Blvd., Suite 200</div>
            <div style="text-align: center; font-weight: bold;">Durham, North Carolina</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;">27703</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-style: italic;">(Address of Principal Executive Offices)</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-style: italic;">(Zip Code)</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center;"><br>
    </div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: center; font-weight: bold;">Employee Stock Purchase Plan</div>
    <div style="text-align: center; font-weight: bold;">(as Amended and Restated March 19, 2020)</div>
    <div style="text-align: center; font-style: italic;">(Full Title of the Plan)<br>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">Jon P. Stonehouse</div>
    <div style="text-align: center; font-weight: bold;">President and Chief Executive Officer</div>
    <div style="text-align: center; font-weight: bold;">BioCryst Pharmaceuticals, Inc.</div>
    <div style="text-align: center; font-weight: bold;">4505 Emperor Blvd., Suite 200</div>
    <div style="text-align: center; font-weight: bold;">Durham, North Carolina 27703</div>
    <div style="text-align: center; font-style: italic;">(Name and Address of Agent for Service)</div>
    <div style="text-align: center;"><br>
    </div>
    <div style="text-align: center; font-weight: bold;">(919) 859-1302</div>
    <div style="text-align: center; font-style: italic;">(Telephone Number, Including Area Code, of Agent for Service)</div>
    <div style="text-align: center;"><br>
    </div>
    <div style="text-align: center; font-style: italic;">Copies to:</div>
    <div style="text-align: center; font-weight: bold;">Brian Lane, Esq.</div>
    <div style="text-align: center; font-weight: bold;">Robyn Zolman, Esq.</div>
    <div style="text-align: center; font-weight: bold;">Gibson, Dunn and Crutcher LLP</div>
    <div style="text-align: center; font-weight: bold;">1050 Connecticut Ave. N.W.</div>
    <div style="text-align: center; font-weight: bold;">Washington, DC 20036</div>
    <div style="text-align: center; font-weight: bold;">(202) 955-8500</div>
    <div style="text-align: center;"><br>
    </div>
    <div>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated
      filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z3e0d3b4cb7fc4d0a8809a4e0a323fb41" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50.45%; vertical-align: bottom;">
            <div>Large accelerated filer &#9744;</div>
          </td>
          <td style="width: 50%; vertical-align: bottom;">
            <div>Accelerated filer &#9746;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.45%; vertical-align: bottom;">
            <div>Non-accelerated filer &#9744;</div>
          </td>
          <td style="width: 50%; vertical-align: bottom;">
            <div>Smaller reporting company &#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.45%; vertical-align: bottom;">&#160;</td>
          <td style="width: 50%; vertical-align: bottom;">
            <div>Emerging growth company &#9744;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
      Securities Act. &#9744;</div>
    <div> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">CALCULATION OF REGISTRATION FEE</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center;">
      <table cellspacing="0" cellpadding="0" border="0" id="z399af66ccc4347748c6ae418062fef9c" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">

          <tr>
            <td valign="bottom" style="vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Title of Securities</div>
              <div style="text-align: center; font-weight: bold;">to be Registered</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="2" style="vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Amount to be</div>
              <div style="text-align: center; font-weight: bold;">Registered (1)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="2" style="vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Proposed Maximum</div>
              <div style="text-align: center; font-weight: bold;">Offering Price Per Share</div>
              <div style="text-align: center; font-weight: bold;">(3)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="2" style="vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Proposed Maximum</div>
              <div style="text-align: center; font-weight: bold;">Aggregate Offering</div>
              <div style="text-align: center; font-weight: bold;">Price (3)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="2" style="vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Amount of</div>
              <div style="text-align: center; font-weight: bold;">Registration Fee (3)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Common Stock, $0.01 par value</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div>3,000,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div>(2)</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div>$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div>4.24</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div>$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div>12,720,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div>$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div>1,651.06</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="ze4535c5079fb4ecbb44214bb71892c8e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; align: right;">(1)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Pursuant to Rule 416(a) under the Securities Act of 1933, this Registration Statement shall also cover any additional shares of Common Stock which become issuable by reason of any stock dividend, stock split, recapitalization or other
              similar transaction effected without the receipt of consideration which results in an increase in the number of the Registrant&#8217;s outstanding shares of Common Stock.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z50358ffefea948b38ff2c8ffc788204d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; align: right;">(2)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Increase in authorized number of shares under the Employee Stock Purchase Plan (as amended and restated March 19, 2020) as approved by the Registrant&#8217;s stockholders in May 2020.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z41089f00a8314f099fd213a29781a4d5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; align: right;">(3)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) under the Securities Act of 1933, as amended, based upon the average of the high and low prices of the Registrant&#8217;s Common Stock on
              June 5, 2020, as reported on The Nasdaq Global Select Market.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">PART I</div>
    <div style="text-align: center;"><br>
    </div>
    <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</div>
    <div style="text-align: center;"><br>
    </div>
    <div style="text-indent: 36pt;">Documents containing the information specified in Part I of Form S-8 have been and/or will be sent or given to employees as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In
      accordance with the instructions of Part I of Form S-8, such documents will not be filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) either as part of this Registration Statement or as prospectuses or prospectus supplements
      pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute the prospectus as required by Section 10(a) of the
      Securities Act.</div>
    <div style="text-indent: 36pt;"><br>
    </div>
    <div style="text-align: center; font-weight: bold;">PART II</div>
    <div style="text-align: center;"><br>
    </div>
    <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>
    <div style="text-align: center;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z2556f22a40f940518a035118bd57efd4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 3.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Incorporation of Documents by Reference.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">The following documents filed by BioCryst Pharmaceuticals, Inc. (the &#8220;Registrant&#8221;) with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), are incorporated by reference in
      this Registration Statement:</div>
    <div style="text-indent: 36pt;"><br>
    </div>
    <div style="text-indent: 36pt;">(a)&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; The Registrant&#8217;s Annual Report on Form 10-K for the year ended <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320001710/f10k_031320p.htm">December 31, 2019</a>, filed with the
      Commission on March 13, 2020 (including the sections of the Registrant&#8217;s proxy statement relating to its <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320002184/def14a_033120.htm">May 12, 2020</a> annual meeting of stockholders
      that are incorporated by reference therein);</div>
    <div style="text-indent: 36pt;"><br>
    </div>
    <div style="text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; The Registrant&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003557/f10q_050820p.htm">March 31, 2020</a>, filed
      with the Commission on May 11, 2020;</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; The Registrant&#8217;s Current Reports on Form 8-K filed with the Commission on <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320000183/f8k_011320.htm">January 13, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320000241/f8k_011520.htm">January 15, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320000650/f8k_020320.htm">February 3, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320001018/f8k_021820.htm">February 18, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320001229/f8k_022520.htm">February 25, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320001491/f8k_030520.htm">March 5, 2020</a> (filing containing Items 8.01 and 9.01 only), <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320001589/f8k_031020.htm">March
        10, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320002124/f8k_033020.htm">March 30, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320002295/f8k_040220.htm">April 2, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320002530/f8k_040920.htm">April 10, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/f8k_051320.htm">May 13, 2020</a> and <a href="http://www.sec.gov/Archives/edgar/data/882796/000114036120012787/nt10011234x7_8k.htm">June 1, 2020</a>; and</div>
    <div style="text-indent: 36pt;"><br>
    </div>
    <div style="text-indent: 36pt;">(d)&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; The description of the Registrant&#8217;s common stock set forth in Exhibit 4.1 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended <a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320001710/exh_41.htm">December 31, 2019</a>, filed with the Commission on March 13, 2020.</div>
    <div style="text-indent: 36pt;"><br>
    </div>
    <div style="text-indent: 36pt;">All reports and other documents subsequently filed with the Commission by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which
      indicates that all securities offered herein have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of
      such documents, excluding any information furnished under Item 7.01 or Item 2.02 of any Current Report on Form 8-K (and corresponding information furnished under Item 9.01 or included as an exhibit thereto). Any statement contained in a document
      incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document
      that also is or is deemed to be incorporated by reference herein modifies or replaces such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration
      Statement.</div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z81bf889cda4b48f09215ca2dde9f7c6a" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold;">Item 4.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;"><font style="font-weight: bold;">Description of Securities.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">Not applicable.</div>
    <div style="text-indent: 36pt;"><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z4badf1322efb41f49b6985961ebbb63a" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold;">Item 5.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;"><font style="font-weight: bold;">Interests of Named Experts and Counsel.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">Not applicable.</div>
    <div style="text-indent: 36pt;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zb44465a5281f4eaaaa25098838ef39d9" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold;">Item 6.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;"><font style="font-weight: bold;">Indemnification of Directors and Officers.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; color: #000000;">Section 145 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) sets forth the circumstances in which a Delaware corporation is permitted and/or required to indemnify its directors and officers. The DGCL
      permits a corporation to indemnify its directors and officers in certain proceedings if the director or officer has complied with the standard of conduct set out in the DGCL. The standard of conduct requires that the director or officer must have
      acted in good faith, in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to matters in a criminal proceeding, the director or officer must have had no reason to believe that
      his or her conduct was unlawful. With respect to suits by or in the right of the corporation, the DGCL permits indemnification of directors and officers if the person meets the standard of conduct, except that it precludes indemnification of
      directors and officers who are adjudged liable to the corporation, unless the Court of Chancery or the court in which the corporation&#8217;s action or suit was brought determines that the director or officer is fairly and reasonably entitled to indemnity
      for expenses. To the extent that a present or former director or officer of the corporation is successful on the merits or otherwise in his or her defense of a proceeding, the corporation is required to indemnify the director or officer against
      reasonable expenses incurred in defending himself or herself. The rights provided in Section 145 of the DGCL are not exclusive, and the corporation may also provide for indemnification under bylaw, agreement, vote of stockholders or disinterested
      directors or otherwise.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; color: #000000;">The Registrant&#8217;s Third Restated Certificate of Incorporation, as amended (the &#8220;Certificate of Incorporation&#8221;), provides for indemnification of any director or officer who was or is a party or is
      threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was, or has agreed to become, a director or officer of the
      Registrant, or is or was serving, or agreed to serve, at the request of the Registrant, as a director, officer or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including any
      employee benefit plan), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or on
      his behalf in connection with such action, suit or proceeding and any appeal therefrom, in each case to the fullest extent permitted by the DGCL. The Registrant shall not indemnify any person seeking indemnification in connection with a proceeding or
      part thereof initiated by such person unless the initiation was approved by the Board of Directors of the Registrant. The Certificate of Incorporation further provides for permissible indemnification of employees and other agents to the maximum
      extent permitted by the DGCL and the Certificate of Incorporation with respect to directors and officers.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; color: #000000;">Section 102(b)(7) of the DGCL provides that a corporation may relieve its directors from personal liability to the corporation or its stockholders for monetary damages for any breach of their fiduciary
      duty as directors except for (i) a breach of the duty of loyalty; (ii) acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; (iii) willful or negligent violations of certain provisions in the DGCL
      imposing certain requirements with respect to stock repurchases, redemptions and dividends; or (iv) for any transactions from which the director derived an improper personal benefit. The Registrant&#8217;s Certificate of Incorporation provides that no
      directors of the Registrant shall be liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director to the fullest extent permitted by the DGCL.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; color: #000000;">In addition, the Registrant currently maintains liability insurance for its directors and officers insuring them against certain liabilities asserted against them in their capacities as directors or
      officers or arising out of such status.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; color: #000000;">The indemnification provisions noted above may be sufficiently broad to permit indemnification of the Registrant&#8217;s officers and directors for liabilities arising under the Securities Act.</div>
    <div style="text-indent: 36pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z04447a1273af435cbbbade5fa962523c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 7.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Exemption from Registration Claimed.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">Not applicable.</div>
    <div style="text-indent: 36pt;"><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="ze1b79e46954b491c98b6c720deb0066c" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold;">Item 8.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;"><font style="font-weight: bold;">Exhibits.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">The following exhibits are submitted herewith or incorporated by reference herein.</div>
    <div style="text-indent: 36pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="ze0eb751c66884fe9bf4885439e650e02" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 10%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">Exhibit</div>
            <div style="text-align: center; font-weight: bold;"><u>Number</u></div>
          </td>
          <td style="width: 90%; vertical-align: bottom;">
            <div>&#160;</div>
            <div style="font-weight: bold;"><u>Description</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: bottom;">&#160;</td>
          <td style="width: 90%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="ex5_1.htm">5.1</a></div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Opinion of Gibson, Dunn and Crutcher LLP (filed herewith).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="ex23_1.htm">23.1</a></div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm (filed herewith).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="ex5_1.htm">23.2</a></div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Consent of Gibson, Dunn and Crutcher LLP (included in Exhibit 5.1).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="#POWEROFATTORNEY">24.1</a></div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Power of Attorney (included on signature page).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_102.htm">99.1</a></div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Employee Stock Purchase Plan, as amended and restated March 19, 2020 (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed on May 13, 2020).</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z855f39400c5e4f16a3c5e5af93a0ed82" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 9.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Undertakings.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">a.&#160; &#160; &#160; &#160; &#160;&#160; The undersigned Registrant hereby undertakes:</div>
    <div style="text-indent: 36pt;"><br>
    </div>
    <div style="text-indent: 72pt;">(1)&#160; &#160; &#160; &#160; &#160; To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</div>
    <div style="text-indent: 72pt;"><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 72pt;">(i)&#160; &#160; &#160; &#160; To include any prospectus required by Section 10(a)(3) of the Securities Act.</div>
    <div style="text-indent: 36pt; margin-left: 72pt;"><br>
    </div>
    <div style="text-indent: 72pt; margin-left: 36pt;">(ii)&#160; &#160; &#160;&#160; To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or
      in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered
      would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the
      changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in this Registration Statement; and</div>
    <div style="text-indent: 72pt; margin-left: 36pt;"><br>
    </div>
    <div style="text-indent: 72pt; margin-left: 36pt;">(iii)&#160; &#160;&#160;&#160; To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this
      Registration Statement;</div>
    <div style="text-indent: 72pt; margin-left: 36pt;"><br>
    </div>
    <div style="text-indent: 71.5pt;"><font style="font-style: italic;">provided, however</font>, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is
      contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.</div>
    <div style="text-indent: 71.5pt;"><br>
    </div>
    <div style="text-indent: 72pt;">(2)&#160; &#160; &#160; &#160; &#160; That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein,
      and the offering of such securities at that time shall be deemed to be the initial <font style="font-style: italic;">bona fide</font> offering thereof.</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;">(3)&#160; &#160; &#160; &#160; &#160; To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
    <div style="text-indent: 72pt;"><br>
    </div>
    <div style="text-indent: 36pt;">b.&#160; &#160; &#160; &#160;&#160; &#160; The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant&#8217;s annual report pursuant to Section 13(a) or Section 15(d)
      of the Exchange Act that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be
      the initial <font style="font-style: italic;">bona fide</font> offering thereof.</div>
    <div style="text-indent: 36pt;"><br>
    </div>
    <div style="text-indent: 36pt;">c.&#160; &#160; &#160; &#160; &#160;&#160; Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or
      otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for
      indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by
      such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
      jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div>
    <div style="text-indent: 36pt;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
    <div style="text-align: center;"><br>
    </div>
    <div style="text-indent: 36pt;">Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration
      Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina, on the 10th day of June, 2020.</div>
    <div style="text-indent: 36pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z598ef32fa29548539ba961f532428297" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: bottom;">&#160;</td>
          <td style="vertical-align: bottom;" colspan="2">
            <div>BIOCRYST PHARMACEUTICALS, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;">&#160;</td>
          <td style="vertical-align: bottom;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;">&#160;</td>
          <td style="width: 5%; vertical-align: bottom;">
            <div>By:</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Jon P. Stonehouse</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;">&#160;</td>
          <td style="width: 5%; vertical-align: bottom;">&#160;</td>
          <td style="width: 45%; vertical-align: bottom;">
            <div>Jon P. Stonehouse</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;">&#160;</td>
          <td style="width: 5%; vertical-align: bottom;">&#160;</td>
          <td style="width: 45%; vertical-align: bottom;">
            <div>President &amp; Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <div style="text-align: center; font-weight: bold;"><a name="POWEROFATTORNEY"><!--Anchor--></a>POWER OF ATTORNEY</div>
      <div style="text-align: center;"><br>
      </div>
      <div style="text-indent: 36pt;">Each of the undersigned officers and directors of BIOCRYST PHARMACEUTICALS, INC. hereby constitutes and appoints Jon P. Stonehouse, Anthony Doyle and Alane P. Barnes, and each of them, as the undersigned&#8217;s true and
        lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the undersigned and in the undersigned&#8217;s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective
        amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and
        authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said
        attorneys-in-fact and agents, or any of them, or any of their substitutes, may lawfully do or cause to be done by virtue hereof.</div>
      <div style="text-indent: 36pt;"><br>
      </div>
      <div style="text-indent: 36pt;">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on June 10, 2020.</div>
      <div style="text-indent: 36pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 39.82%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><u>Signature</u></div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><u>Title</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">&#160;</td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;/s/ Jon P. Stonehouse</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">
              <div style="text-align: center;">President, Chief Executive Officer and Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">
              <div>Jon P. Stonehouse</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">
              <div style="text-align: center;">(Principal Executive Officer)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">&#160;</td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;/s/ Anthony Doyle</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">
              <div style="text-align: center;">Senior Vice President and Chief Financial Officer</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: bottom;">
              <div>Anthony Doyle</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">
              <div style="text-align: center;">(Principal Financial Officer)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: bottom;" rowspan="1">&#160;</td>
            <td style="width: 0.65%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1">
              <div>/s/ Michael L. Jones</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;" rowspan="1">
              <div style="text-align: center;">Executive Director, Finance and Principal Accounting Officer</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">
              <div>Michael L. Jones</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">
              <div style="text-align: center;">(Principal Accounting Officer)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">&#160;</td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;/s/ George B. Abercrombie</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">
              <div style="text-align: center;">Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">
              <div>George B. Abercrombie</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">&#160;</td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;/s/ Stephen J. Aselage</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">
              <div style="text-align: center;">Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">
              <div>Stephen J. Aselage</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">&#160;</td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;/s/ Theresa M. Heggie</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">
              <div style="text-align: center;">Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">
              <div>Theresa M. Heggie</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">&#160;</td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;/s/ Nancy Hutson, Ph.D.</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">
              <div style="text-align: center;">Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">
              <div>Nancy Hutson, Ph.D.</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">&#160;</td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;/s/ Robert. A Ingram</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">
              <div style="text-align: center;">Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">
              <div>Robert. A Ingram</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">&#160;</td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;/s/ Kenneth B. Lee, Jr.</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">
              <div style="text-align: center;">Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">
              <div>Kenneth B. Lee, Jr.</div>
              <div>&#160;</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;/s/ Alan G. Levin</div>
            </td>
            <td style="width: 0.65%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">
              <div style="text-align: center;">Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div>Alan G. Levin</div>
            </td>
            <td style="width: 0.65%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top;">&#160;</td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;/s/ Helen Thackray, M.D.</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">
              <div style="text-align: center;">Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.82%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div>Helen Thackray, M.D.</div>
            </td>
            <td style="width: 0.65%; vertical-align: top;">&#160;</td>
            <td style="width: 59.47%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div style="text-align: center; font-weight: bold;"><a name="a_001"></a></div>
  </div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "forms8.htm", "description": "S-8", "secsgml_size_bytes": 62646}]
{"company-data": {"conformed-name": "BIOCRYST PHARMACEUTICALS INC", "cik": "0000882796", "assigned-sic": "2836", "irs-number": "621413174", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-239077", "film-number": "20955026"}, "business-address": {"street1": "4505 EMPEROR BOULEVARD", "street2": "SUITE 200", "city": "DURHAM", "state": "NC", "zip": "27703", "phone": "919-859-1302"}, "mail-address": {"street1": "4505 EMPEROR BOULEVARD", "street2": "SUITE 200", "city": "DURHAM", "state": "NC", "zip": "27703"}}
As filed with the Securities and Exchange Commission on June 10, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
BIOCRYST PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
62-1413174
(State of Incorporation)
(I.R.S. Employer Identification No.)
4505 Emperor Blvd., Suite 200
Durham, North Carolina
27703
(Address of Principal Executive Offices)
(Zip Code)
Employee Stock Purchase Plan
(as Amended and Restated March 19, 2020)
(Full Title of the Plan)
Jon P. Stonehouse
President and Chief Executive Officer
BioCryst Pharmaceuticals, Inc.
4505 Emperor Blvd., Suite 200
Durham, North Carolina 27703
(Name and Address of Agent for Service)
(919) 859-1302
(Telephone Number, Including Area Code, of Agent for Service)
Copies to:
Brian Lane, Esq.
Robyn Zolman, Esq.
Gibson, Dunn and Crutcher LLP
1050 Connecticut Ave. N.W.
Washington, DC 20036
(202) 955-8500
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated
      filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer ☒
Non-accelerated filer ☐
Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
      Securities Act. ☐
CALCULATION OF REGISTRATION FEE
Title of Securities
to be Registered
Amount to be
Registered (1)
Proposed Maximum
Offering Price Per Share
(3)
Proposed Maximum
Aggregate Offering
Price (3)
Amount of
Registration Fee (3)
Common Stock, $0.01 par value
3,000,000
(2)
$
4.24
$
12,720,000
$
1,651.06
(1)
Pursuant to Rule 416(a) under the Securities Act of 1933, this Registration Statement shall also cover any additional shares of Common Stock which become issuable by reason of any stock dividend, stock split, recapitalization or other
              similar transaction effected without the receipt of consideration which results in an increase in the number of the Registrant's outstanding shares of Common Stock.
(2)
Increase in authorized number of shares under the Employee Stock Purchase Plan (as amended and restated March 19, 2020) as approved by the Registrant's stockholders in May 2020.
(3)
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) under the Securities Act of 1933, as amended, based upon the average of the high and low prices of the Registrant's Common Stock on
              June 5, 2020, as reported on The Nasdaq Global Select Market.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Documents containing the information specified in Part I of Form S-8 have been and/or will be sent or given to employees as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act"). In
      accordance with the instructions of Part I of Form S-8, such documents will not be filed with the Securities and Exchange Commission (the "Commission") either as part of this Registration Statement or as prospectuses or prospectus supplements
      pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute the prospectus as required by Section 10(a) of the
      Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3.
Incorporation of Documents by Reference.
The following documents filed by BioCryst Pharmaceuticals, Inc. (the "Registrant") with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are incorporated by reference in
      this Registration Statement:
(a)                 The Registrant's Annual Report on Form 10-K for the year ended
December 31, 2019
, filed with the
      Commission on March 13, 2020 (including the sections of the Registrant's proxy statement relating to its
May 12, 2020
annual meeting of stockholders
      that are incorporated by reference therein);
(b)                 The Registrant's Quarterly Report on Form 10-Q for the quarterly period ended
March 31, 2020
, filed
      with the Commission on May 11, 2020;
(c)                 The Registrant's Current Reports on Form 8-K filed with the Commission on
January 13, 2020
,
January 15, 2020
,
February 3, 2020
,
February 18, 2020
,
February 25, 2020
,
March 5, 2020
(filing containing Items 8.01 and 9.01 only),
March
        10, 2020
,
March 30, 2020
,
April 2, 2020
,
April 10, 2020
,
May 13, 2020
and
June 1, 2020
; and
(d)                 The description of the Registrant's common stock set forth in Exhibit 4.1 to the Registrant's Annual Report on Form 10-K for the year ended
December 31, 2019
, filed with the Commission on March 13, 2020.
All reports and other documents subsequently filed with the Commission by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which
      indicates that all securities offered herein have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of
      such documents, excluding any information furnished under Item 7.01 or Item 2.02 of any Current Report on Form 8-K (and corresponding information furnished under Item 9.01 or included as an exhibit thereto). Any statement contained in a document
      incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document
      that also is or is deemed to be incorporated by reference herein modifies or replaces such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration
      Statement.
Item 4.
Description of Securities.
Not applicable.
Item 5.
Interests of Named Experts and Counsel.
Not applicable.
Item 6.
Indemnification of Directors and Officers.
Section 145 of the Delaware General Corporation Law (the "DGCL") sets forth the circumstances in which a Delaware corporation is permitted and/or required to indemnify its directors and officers. The DGCL
      permits a corporation to indemnify its directors and officers in certain proceedings if the director or officer has complied with the standard of conduct set out in the DGCL. The standard of conduct requires that the director or officer must have
      acted in good faith, in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to matters in a criminal proceeding, the director or officer must have had no reason to believe that
      his or her conduct was unlawful. With respect to suits by or in the right of the corporation, the DGCL permits indemnification of directors and officers if the person meets the standard of conduct, except that it precludes indemnification of
      directors and officers who are adjudged liable to the corporation, unless the Court of Chancery or the court in which the corporation's action or suit was brought determines that the director or officer is fairly and reasonably entitled to indemnity
      for expenses. To the extent that a present or former director or officer of the corporation is successful on the merits or otherwise in his or her defense of a proceeding, the corporation is required to indemnify the director or officer against
      reasonable expenses incurred in defending himself or herself. The rights provided in Section 145 of the DGCL are not exclusive, and the corporation may also provide for indemnification under bylaw, agreement, vote of stockholders or disinterested
      directors or otherwise.
The Registrant's Third Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), provides for indemnification of any director or officer who was or is a party or is
      threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was, or has agreed to become, a director or officer of the
      Registrant, or is or was serving, or agreed to serve, at the request of the Registrant, as a director, officer or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including any
      employee benefit plan), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or on
      his behalf in connection with such action, suit or proceeding and any appeal therefrom, in each case to the fullest extent permitted by the DGCL. The Registrant shall not indemnify any person seeking indemnification in connection with a proceeding or
      part thereof initiated by such person unless the initiation was approved by the Board of Directors of the Registrant. The Certificate of Incorporation further provides for permissible indemnification of employees and other agents to the maximum
      extent permitted by the DGCL and the Certificate of Incorporation with respect to directors and officers.
Section 102(b)(7) of the DGCL provides that a corporation may relieve its directors from personal liability to the corporation or its stockholders for monetary damages for any breach of their fiduciary
      duty as directors except for (i) a breach of the duty of loyalty; (ii) acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; (iii) willful or negligent violations of certain provisions in the DGCL
      imposing certain requirements with respect to stock repurchases, redemptions and dividends; or (iv) for any transactions from which the director derived an improper personal benefit. The Registrant's Certificate of Incorporation provides that no
      directors of the Registrant shall be liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director to the fullest extent permitted by the DGCL.
In addition, the Registrant currently maintains liability insurance for its directors and officers insuring them against certain liabilities asserted against them in their capacities as directors or
      officers or arising out of such status.
The indemnification provisions noted above may be sufficiently broad to permit indemnification of the Registrant's officers and directors for liabilities arising under the Securities Act.
Item 7.
Exemption from Registration Claimed.
Not applicable.
Item 8.
Exhibits.
The following exhibits are submitted herewith or incorporated by reference herein.
Exhibit
Number
Description
5.1
Opinion of Gibson, Dunn and Crutcher LLP (filed herewith).
23.1
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm (filed herewith).
23.2
Consent of Gibson, Dunn and Crutcher LLP (included in Exhibit 5.1).
24.1
Power of Attorney (included on signature page).
99.1
Employee Stock Purchase Plan, as amended and restated March 19, 2020 (incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed on May 13, 2020).
Item 9.
Undertakings.
a.           The undersigned Registrant hereby undertakes:
(1)          To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i)        To include any prospectus required by Section 10(a)(3) of the Securities Act.
(ii)       To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or
      in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered
      would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the
      changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in this Registration Statement; and
(iii)      To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this
      Registration Statement;
provided, however
, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is
      contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
(2)          That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein,
      and the offering of such securities at that time shall be deemed to be the initial
bona fide
offering thereof.
(3)          To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
b.           The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d)
      of the Exchange Act that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be
      the initial
bona fide
offering thereof.
c.           Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or
      otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for
      indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by
      such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
      jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration
      Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina, on the 10th day of June, 2020.
BIOCRYST PHARMACEUTICALS, INC.
By:
/s/ Jon P. Stonehouse
Jon P. Stonehouse
President & Chief Executive Officer
POWER OF ATTORNEY
Each of the undersigned officers and directors of BIOCRYST PHARMACEUTICALS, INC. hereby constitutes and appoints Jon P. Stonehouse, Anthony Doyle and Alane P. Barnes, and each of them, as the undersigned's true and
        lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective
        amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and
        authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said
        attorneys-in-fact and agents, or any of them, or any of their substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on June 10, 2020.
Signature
Title
/s/ Jon P. Stonehouse
President, Chief Executive Officer and Director
Jon P. Stonehouse
(Principal Executive Officer)
/s/ Anthony Doyle
Senior Vice President and Chief Financial Officer
Anthony Doyle
(Principal Financial Officer)
/s/ Michael L. Jones
Executive Director, Finance and Principal Accounting Officer
Michael L. Jones
(Principal Accounting Officer)
/s/ George B. Abercrombie
Director
George B. Abercrombie
/s/ Stephen J. Aselage
Director
Stephen J. Aselage
/s/ Theresa M. Heggie
Director
Theresa M. Heggie
/s/ Nancy Hutson, Ph.D.
Director
Nancy Hutson, Ph.D.
/s/ Robert. A Ingram
Director
Robert. A Ingram
/s/ Kenneth B. Lee, Jr.
Director
Kenneth B. Lee, Jr.
/s/ Alan G. Levin
Director
Alan G. Levin
/s/ Helen Thackray, M.D.
Director
Helen Thackray, M.D.